A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Phase 3

Recruiting

• Conditions: Sjögren's Syndrome (SS)
• Interventions: Drug: Dazodalibep; Drug: Placebo

• Registration Number: NCT06245408
• Lead Sponsor: Amgen

Brief Summary

Primary Objective:

To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state

Secondary Objectives:

1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS.

2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS

3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS

Detailed Description

Acquired from Horizon in 2024.

Study Timeline

• Study First Submitted: 2024-01-30
• Study First Submitted QC: 2024-01-30
• Study First Posted: 2024-02-07
• Study Start: 2024-04-08
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-19
• Last Update Posted: 2025-06-22
• Primary Completion: 2026-09-02
• Study Completion: 2026-11-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 435

Inclusion Criteria

1. Diagnosed with SS by meeting the 2016 ACR/EULAR Classification Criteria

2. Have an ESSPRI score of ≥ 5 at screening.

3. Have an ESSDAI score of < 5 at screening.

4. Positive for either anti-Ro autoantibodies or RF, or both at screening (as per the definition of the standard central laboratory test).

5. Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min.

6. Vaccinated against SARS-CoV-2 according to current local authority guidelines at least 2 weeks prior to screening unless participant refuses vaccination.

7. Meets all of the following tuberculosis (TB) criteria:

   1. No history of latent or active TB prior to screening, except for latent TB with documented completion of locally appropriate treatment.
   2. No signs or symptoms suggestive of active TB from medical history or physical examination.
   3. No recent (≤ 12 weeks of screening) close contact with a person with active TB (close contact is defined as ≥ 4 hours/week OR living in the same household OR in a house where a person with active TB is a frequent visitor).
   4. Negative Interferon Gamma Release Assay (IGRA) test result for TB at screen unless previously treated as per Inclusion Criterion. Participants with an indeterminate test result can repeat the test, but if the repeat test is also indeterminate, they are excluded.
   5. A chest radiograph (obtained during the screening period or any time within 12 weeks prior to screening) with no evidence of current active TB or other infection, or prior TB, malignancy, or clinically significant abnormalities suggesting an active process (unless due to SS).

Key

Exclusion Criteria

1. Individuals with medical history of confirmed deep venous thrombosis, pulmonary embolism, or arterial thromboembolism within 2 years of screening.

2. History or presence of concomitant polymyositis or dermatomyositis or systemic sclerosis.

3. Active malignancy or history of malignancy within the last 5 years, except as follows:

   1. In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to screening; OR
   2. Cutaneous basal cell carcinoma following presumed curative therapy.

4. Individuals who are pregnant or lactating or planning to become pregnant during the study.

5. Individuals with known history of severe allergy or reaction to any component of the IP formulation or to any other biologic therapy.

6. Individuals with any severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder or any other condition that, in the opinion of the Investigator, would place the individual at unacceptable risk of complications, interfere with evaluation of the IP, or confound the interpretation of participant safety or study results.

7. Individuals who have a positive test for, or have been treated for, hepatitis B, hepatitis c or HIV infection.

8. Individuals with a positive test for SARS-CoV-2 on the day of randomization or symptoms suggestive of SARS-CoV-2 at randomization or significant exposure to coronavirus disease 2019 (COVID-19) within 10 calendar days prior to randomization.

9. Individuals with:

   1. A history of more than one episode of herpes zoster and/or opportunistic infections in the last 12 months, with the exception of non-invasive herpes simplex at any site, oral candidiasis, vaginal candidiasis, or cutaneous fungal infections, which are permitted within the prior 12 months unless of unusual severity.
   2. Active infection requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring IV antibiotics within 12 months prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dazodalibep Dose 1	Dazodalibep	Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
Dazodalibep Dose 2	Dazodalibep	Participants will be administered dose 2 of dazodalibep by IV infusion.
Placebo	Placebo	Participants will be administered placebo by IV infusion.

Primary Outcome Measures

Name	Time	Method
Change from baseline in Diary for Assessing Sjogren's Patient Reported Index (DASPRI ) score	At week 48
Change from baseline in ESSPRI score	At Week 48

Secondary Outcome Measures

Name	Time	Method
Change from baseline in total stimulated salivary flow	At Week 48
Proportion of participants achieving ESSPRI [1.5] response	At Week 48
Number of participants With Adverse Events of Special Interest (AESIs)	Baseline (Day 1) to Week 56
Proportion of participants achieving meaningful improvement in DASPRI	At Week 48
Change from baseline in Patient-Reported Outcomes Measurement Information System Fatigue-Short Form 10a (PROMIS-Fatigue SF-10a)	At Week 48
Change from baseline in DASPRI Pain	At Week 48
Change from baseline in ESSPRI Pain	At Week 48
Change from baseline in ESSPRI fatigue domain score	At Week 48
Change from baseline in 36-item Short Form Survey (SF-36) Physical Component Summary (PCS) score	At Week 48
Change from baseline in DASPRI total score	At week 12 and week 24
Change from baseline in DASPRI Dryness	At Week 48
Change from baseline in ESSPRI Dryness	At Week 48
Change from baseline in ESSPRI total score	At week 12, Week 24
Change from baseline in DASPRI Fatigue	At Week 48
Number of participants With Treatment Emergent Adverse Events (TEAEs)	Baseline (Day 1) to Week 56
Number of participants With Treatment Emergent Serious Adverse Events (TESAEs)	Baseline (Day 1) to Week 56

Trial Locations

Locations (203)

Arizona Research Clinic PLLC; 🇺🇸 Chandler, Arizona, United States

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln; 🇺🇸 Flagstaff, Arizona, United States

Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St; 🇺🇸 Gilbert, Arizona, United States

Arizona Arthritis and Rheumatology Associates - Glendale - 5681 W Beverly Ln; 🇺🇸 Glendale, Arizona, United States

Arizona Arthritis and Rheumatology Associates - Tucson - 2001 W Orange Grove Rd; 🇺🇸 Tucson, Arizona, United States

Samy Metyas MD Inc; 🇺🇸 Covina, California, United States

UCSD Altman Clinical and Translational Research Institute Building; 🇺🇸 La Jolla, California, United States

Inland Rheumatology Clinical Trials Incorporated; 🇺🇸 Upland, California, United States

Medvin Clinical Research; 🇺🇸 Whittier, California, United States

Tekton Research, LLC - 2121 E Harmony Rd - PPDS; 🇺🇸 Fort Collins, Colorado, United States

Scroll for more (193 remaining)